Skip to content

Study · Randomized controlled trial · n = 27 · 2002

3 results

Effects of a growth hormone receptor antagonist on bone markers in acromegaly.

Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S, Kleinberg D, Klibanski A

Clinical endocrinology1 Sept 2002Cited by 28 (Europe PMC)

PMID12201832 (opens in a new tab)DOI10.1046/j.1365-2265.2002.01624.x (opens in a new tab)PepBankPUB-12201832
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients, pegvisomant reduced osteocalcin versus placebo (-2.2 +/- 0.44 versus +0.01 +/- 0.39 nmol/l, P = 0.009).

    In plain wordsIn acromegaly patients, pegvisomant reduced the bone formation marker osteocalcin more than placebo.

    Peptide
    Pegvisomant
    Outcome
    DecreaseOsteocalcin change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10, 15 or 20 mg · 12 weeksAs given in this study (human).

    Measurements

    Osteocalcin change
    −2.2 nmol/l
    pegvisomant
    Osteocalcin change
    0.01 nmol/l
    placebo

    Source sentences

    Summary
    During the 12-week placebo-controlled period, there were significant decreases in serum markers of bone formation, osteocalcin (-2.2 +/- 0.44 vs. placebo +0.01 +/- 0.39 nmol/l, P = 0.009)
    2 context sentences
    Summary · context
    Twenty-seven patients with acromegaly were enrolled as part of a multicentre 12-week trial of a GH receptor antagonist and were randomized to placebo (n = 7) or 10, 15 or 20 mg of pegvisomant (n = 20).
    Summary · context
    Serum markers of bone turnover were determined at baseline and 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients, pegvisomant reduced PICP versus placebo (-23.6 +/- 9.6 versus +18.1 +/- 12.8 micro g/l, P = 0.022).

    In plain wordsIn acromegaly patients, pegvisomant reduced the bone formation marker PICP more than placebo.

    Peptide
    Pegvisomant
    Outcome
    DecreasePICP change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10, 15 or 20 mg · 12 weeksAs given in this study (human).

    Measurements

    PICP change
    −23.6 micro g/l
    pegvisomant
    PICP change
    18.1 micro g/l
    placebo

    Source sentences

    Summary
    and PICP (-23.6 +/- 9.6 vs. placebo +18.1 +/- 12.8 micro g/l, P = 0.022)
    2 context sentences
    Summary · context
    Twenty-seven patients with acromegaly were enrolled as part of a multicentre 12-week trial of a GH receptor antagonist and were randomized to placebo (n = 7) or 10, 15 or 20 mg of pegvisomant (n = 20).
    Summary · context
    Serum markers of bone turnover were determined at baseline and 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In acromegaly patients, pegvisomant reduced NTx versus placebo (-4.4 +/- 1.4 versus +1.0 +/- 0.3 nm, P = 0.024).

    In plain wordsIn acromegaly patients, pegvisomant reduced the bone resorption marker NTx more than placebo.

    Peptide
    Pegvisomant
    Outcome
    DecreaseNTx change
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10, 15 or 20 mg · 12 weeksAs given in this study (human).

    Measurements

    NTx change
    −4.4 nm
    pegvisomant
    NTx change
    1 nm
    placebo

    Source sentences

    Summary
    and a serum marker of bone resorption, NTx (-4.4 +/- 1.4, placebo +1.0 +/- 0.3 nm, P = 0.024).
    2 context sentences
    Summary · context
    Twenty-seven patients with acromegaly were enrolled as part of a multicentre 12-week trial of a GH receptor antagonist and were randomized to placebo (n = 7) or 10, 15 or 20 mg of pegvisomant (n = 20).
    Summary · context
    Serum markers of bone turnover were determined at baseline and 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.